Evidence map›Paper›PMID 34386403›Full record

ArticleAsia Pacific allergy2021

Successful treatment of a patient with adult food allergy and severe asthma using omalizumab.

Miyuki Nishie, Katsunori Masaki, Shinichi Okuzumi, Takao Mochimaru, Hiroki Kabata, Jun Miyata, Hayato Takahashi, Koichi Fukunaga

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Asia Pacific allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Miyuki NishieDivision of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0003-1930-3477
Katsunori MasakiDivision of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0003-0909-9409
Shinichi OkuzumiDivision of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-4092-238X
Takao MochimaruKeio Allergy Center, Keio University Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0002-1505-6651
Hiroki KabataDivision of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0001-8853-6149
Jun MiyataKeio Allergy Center, Keio University Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0002-3189-1702
Hayato TakahashiKeio Allergy Center, Keio University Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0001-6768-8821
Koichi FukunagaDivision of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0001-7460-1990
Keio University · JPKeio University Hospital · JPNational Defense Medical College · JPNational Hospital Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Food allergy is a typical immediate-onset allergic disease in which symptoms are provoked by exposure to the sensitized antigens. Although previous reports have shown that omalizumab has helped children with egg or milk allergy achieve oral immunotherapy safely, there is still no established method for induction of remission in adult food allergy. A 51-year-old woman with oral steroid-dependent severe asthma was treated with omalizumab for 6 years. She had shellfish and wheat food allergy and oral allergy syndrome induced by kiwi and other foods associated with latex-fruit syndrome. Since omalizumab treatment, her food allergy symptoms had disappeared. After 7 years of this treatment, disseminated erythema suddenly appeared; omalizumab was discontinued because of suspected drug-induced eruption. After omalizumab interruption, she felt an itching sensation in her throat with worsened asthma control immediately after wheat ingestion. Readministration of omalizumab improved these symptoms. Thus, we raised the possibility that omalizumab not only improved asthma control but also induced pharmacological remission of the patient's food allergy. Omalizumab may be considered as a treatment option for adult patients with food allergies and severe asthma.

Indexed as

AsthmaFood allergyLatex-fruit syndromeOmalizumabOral allergy syndromeQuality of life

Identifiers

PMID34386403
PMCPMC8331258
OpenAlexW3177793101

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.